“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Opinion|Videos|February 14, 2025 (Updated: January 31, 2025)
Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
This segment examines the evidence supporting cilta-cel in second-line therapy, highlighting key outcomes from the CARTITUDE trials and comparing them to other available second-line treatment options for multiple myeloma.
Advertisement
Video content above is prompted by the following:
- Please discuss the evidence supporting cilta-cel in second-line therapy.
- Which key outcomes from the CARTITUDE trials guide your decision to choose cilta-cel in the second-line setting?
- How do these findings compare with other available second-line treatments for multiple myeloma in this patient group?
Advertisement
Related to this article
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
4
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
5